Travere licenses BTK inhibitor civorebrutinib for $112.5M upfront, up to $1.03B in milestones

Filed June 2, 2026 · Period ending June 1, 2026 · ~1 min read

Key Changes

• high

  Travere acquired exclusive rights to develop and commercialize civorebrutinib, a reversible BTK inhibitor, outside China and certain Asian markets. The deal targets immune-mediated kidney diseases and expands the company's pipeline with a potentially differentiated therapy.

  Item 1.01 verify on EDGAR →
• high

  Company must pay $112.5 million upfront to Everest Medicines, representing a significant immediate cash outflow that will impact balance sheet and potentially affect cash runway and future financing needs.

  Item 1.01 verify on EDGAR →
• high

  Everest eligible for up to $1.03 billion in milestone payments across five indications, plus tiered royalties ranging from high single-digit to double-digit percentages based on annual net sales thresholds.

  Item 1.01 verify on EDGAR →